Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mk-0773. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-0773 SCHEMBL14355641 | 1.00 | AR (1.00) | ARSRD5A2 | |
| Mk-0773 SCHEMBL14387329 | 1.00 | AR (1.00) | ARSRD5A2 | |
| Mk-0773 SCHEMBL13935743 | 0.90 | AR (0.81) | ARSRD5A2 | |
| Mk-0773 SCHEMBL4169171 | 0.90 | AR (0.81) | ARSRD5A2 | |
| Mk-0773 SCHEMBL13604131 | 0.90 | AR (0.81) | ARSRD5A2 | |
| Mk-0773 SCHEMBL4169174 | 0.90 | AR (0.81) | ARSRD5A2 | |
| SCHEMBL4188011 | 0.89 | AR (0.81) | ARSRD5A2 | |
| SCHEMBL4188008 | 0.89 | AR (0.81) | ARSRD5A2 | |
| SCHEMBL4187544 | 0.84 | AR (0.73) | ARSRD5A2 | |
| SCHEMBL4187547 | 0.84 | AR (0.73) | ARSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070133-A | Pharmaceutical compositions containing androgen receptor inhibitors/antagonists, methods and uses | 苏州开拓药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2025051237-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANDROGEN RECEPTOR INHIBITOR/ANTAGONIST, METHOD AND USE | 苏州开拓药业股份有限公司 | 2025-03-13 | — | — | WO | claimed |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | claimed |
| EP-4334314-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| CN-117580839-A | Anti-cancer nuclear hormone receptor targeting compounds | 诺维逊生物股份有限公司 | 2024-02-20 | — | — | CN | claimed |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-12-01 | — | — | US | claimed |
| WO-2022235585-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | claimed |
| CN-122070133-A | Pharmaceutical compositions containing androgen receptor inhibitors/antagonists, methods and uses | 苏州开拓药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12329746-B2 | AR+breast cancer treatment methods | ELLIPSES PHARMA LTD (GB) | 2025-06-17 | — | — | US | disclosed |
| EP-4565324-A1 | VITAMIN A-FREE NUTRITIONAL COMPOSITIONS FOR TREATING DYSFUNCTION OF LIVER FAT METABOLISM | Leibniz-Institut für Altersforschung Fritz-Lipmann-Institut e.V. (FLI) (DE) | 2025-06-11 | — | — | EP | disclosed |
| EP-4066827-A1 | AR+ BREAST CANCER TREATMENT METHODS | Ellipses Pharma Ltd (GB) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-4058464-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3474841-B1 | AR+ BREAST CANCER TREATMENT METHODS | ELLIPSES PHARMA LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885SRD5A2 117/4885 |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885SRD5A2 117/4885 |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | AR 4/4885SRD5A2 63/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | AR 5/4885SRD5A2 46/4885 |
| US-12329746-B2 | AR+breast cancer treatment methods | BRCA1, AR, PARP6 | AR 2/4885SRD5A2 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.